Leicester Professor becomes British Cardiovascular Society President

Congratulations to Professor André Ng, who has officially taken over as President of the British Cardiovascular Society (BCS) at its 2024 AGM in Manchester.

On beginning his three-year term, Professor Ng, who is Professor of Cardiac Electrophysiology and Head of Department of Cardiovascular Sciences at the University of Leicester and Consultant Cardiologist at University Hospitals of Leicester NHS Trust said: “I’m very much looking forward to leading the Society and representing the UK cardiovascular workforce.

“As President of the BCS I plan to drive forward the Society’s great achievements in education, championing excellence in cardiovascular care and leadership in UK cardiology.”

Professor Ng has served the British Cardiovascular Society over the past seven years, with seats on the BCS Board, BCS Council and the BCS Executive and Education Committees, as Chair of the Programmes Committee and as Vice-President for four years.

Professor Tom Robinson, Pro Vice-Chancellor, Head of the College of Life Sciences and Dean of the Medicine at the University of Leicester, said: "I am delighted to hear of Professor Ng's appointment as President of the British Cardiovascular Society. This is an important position for the UK's cardiovascular community and recognises the esteem in which Andre is held by his colleagues.

"The appointment is further recognition of his research leadership and follows the University's recent success in being awarded a British Heart Foundation Centre for Research Excellence, which was led by Professor Ng as Director."

Some £3 million funding has been awarded to the University by the British Heart Foundation to support its world-class cardiovascular disease research over the next five years.

The University has pledged to match this award with additional funding from the University Hospitals of Leicester, taking the total investment in cardiovascular disease research to around £7 million.

Funding will support the University to expand its ground-breaking studies into the causes of common and rare cardiovascular diseases, as well as refining appropriate treatments and interventions.